FMR LLC lifted its position in Intra-Cellular Therapies Inc (NASDAQ:ITCI) by 0.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,204,457 shares of the biopharmaceutical company’s stock after buying an additional 2,390 shares during the period. FMR LLC owned approximately 15.00% of Intra-Cellular Therapies worth $144,973,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently added to or reduced their stakes in the company. Atlantic Trust Group LLC bought a new stake in Intra-Cellular Therapies during the first quarter worth approximately $215,000. D.A. Davidson & CO. bought a new stake in Intra-Cellular Therapies during the first quarter worth approximately $363,000. MetLife Investment Advisors LLC increased its stake in Intra-Cellular Therapies by 15.4% during the first quarter. MetLife Investment Advisors LLC now owns 19,606 shares of the biopharmaceutical company’s stock worth $413,000 after acquiring an additional 2,613 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in Intra-Cellular Therapies by 19.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 20,462 shares of the biopharmaceutical company’s stock worth $362,000 after acquiring an additional 3,400 shares during the last quarter. Finally, ETF Managers Group LLC bought a new stake in Intra-Cellular Therapies during the first quarter worth approximately $460,000. Hedge funds and other institutional investors own 71.53% of the company’s stock.
Several brokerages have weighed in on ITCI. ValuEngine cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th. BidaskClub lowered Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Friday, June 22nd. Royal Bank of Canada restated a “buy” rating and set a $35.00 target price on shares of Intra-Cellular Therapies in a research report on Friday, August 3rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $32.00 price target on shares of Intra-Cellular Therapies in a report on Thursday. Finally, Canaccord Genuity set a $31.00 price target on Intra-Cellular Therapies and gave the company a “buy” rating in a report on Thursday, August 2nd. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $28.00.
NASDAQ:ITCI traded down $0.70 during trading hours on Friday, reaching $19.41. The company’s stock had a trading volume of 335,615 shares, compared to its average volume of 408,049. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -9.16 and a beta of 0.84. Intra-Cellular Therapies Inc has a 12 month low of $13.93 and a 12 month high of $25.82.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. As a group, equities analysts anticipate that Intra-Cellular Therapies Inc will post -3.15 earnings per share for the current fiscal year.
Intra-Cellular Therapies Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.
Further Reading: How are the companies in the S&P 500 selected?
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.